In a meta-analysis study by Jiang Y et al. [50], the results have shown that visfatin levels in patients with MS are significantly higher than healthy subjects in the control group, and maybe visfatin can be used to predict the occurrence of MS. The gene discussed is NAMPT; the disease is myeloid sarcoma.